TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25528557

Group type: EXPERIMENTAL
Intervention: Portrayals of untreated schizophrenia, depression, and heroin addiction
Number of subjects: 3940

Group type: EXPERIMENTAL
Intervention: Portrayals of successfully treated schizophrenia, prescription painkiller addiction, and heroin addiction
Number of subjects: 3940

Group type: COMPARATOR
Intervention: Control vignette
Number of subjects: 3940
Study: 22749926

Group type: EXPERIMENTAL
Intervention: Chewing tobacco containing nicotine for 1 hour after TDT training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control substance without nicotine
Number of subjects: 0
Study: 21477846

Group type: EXPERIMENTAL
Intervention: Tinzaparin 175 IU/kg once daily
Number of subjects: 539

Group type: COMPARATOR
Intervention: Activated partial thromboplastin time‐adjusted UFH twice daily
Number of subjects: 539

Group type: EXPERIMENTAL
Intervention: Tinzaparin
Number of subjects: 539

Group type: COMPARATOR
Intervention: UFH
Number of subjects: 539
Study: 18651985

Group type: EXPERIMENTAL
Intervention: Tele-based nurse delivered five session decision support/psychosocial intervention
Number of subjects: 700

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 700
Study: 17029522

Group type: EXPERIMENTAL
Intervention: Tribochemical silica coating combined with silane
Number of subjects: 20

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 20
Study: 15241100

Group type: EXPERIMENTAL
Intervention: Bird 8400 STi ventilator at 5 breaths/min
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Bird 8400 STi ventilator at 10 breaths/min
Number of subjects: 8

Group type: COMPARATOR
Intervention: Servo‐300 ventilator at 5 breaths/min
Number of subjects: 8

Group type: COMPARATOR
Intervention: Servo‐300 ventilator at 10 breaths/min
Number of subjects: 8
Study: 11531035

Group type: EXPERIMENTAL
Intervention: Emergency oxygen device 1
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Emergency oxygen device 2
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Emergency oxygen device 3
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Emergency oxygen device 4
Number of subjects: 9
Study: 9160033

Group type: EXPERIMENTAL
Intervention: lodoxamide tromethamine 0.1%
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study: 7956336

Group type: EXPERIMENTAL
Intervention: Tretinoin cream (0.025 percent) applied daily for seven months
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 11
Study: 3262546

Group type: EXPERIMENTAL
Intervention: miocamycin 50 mg/kg.day
Number of subjects: 23

Group type: COMPARATOR
Intervention: amoxycillin 60 mg/kg.day
Number of subjects: 23
Study: 31125988

Group type: EXPERIMENTAL
Intervention: 2 mg nicotine gum
Number of subjects: 369

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 369
Study: 31317669

Group type: EXPERIMENTAL
Intervention: Calcium phosphate (CaP)‐coated SLA surface implants
Number of subjects: 34

Group type: COMPARATOR
Intervention: Conventional SLA surface implants
Number of subjects: 34
Study: 27690294

Group type: EXPERIMENTAL
Intervention: CIK cell immunotherapy combined with standard TMZ chemoradiotherapy
Number of subjects: 180

Group type: COMPARATOR
Intervention: Standard TMZ chemoradiotherapy alone (control group)
Number of subjects: 180
Study: 24645829

Group type: EXPERIMENTAL
Intervention: Smart phone-based app (EPI app) used by village doctors
Number of subjects: 36

Group type: COMPARATOR
Intervention: Usual immunization management by village doctors (Control)
Number of subjects: 36
Study: 22834649

Group type: EXPERIMENTAL
Intervention: Transdermal 1% testosterone gel (5-7.5 mg/day)
Number of subjects: 362

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 362
Study: 20485136

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 838

Group type: COMPARATOR
Intervention: Control
Number of subjects: 838
Study: 18046027

Group type: EXPERIMENTAL
Intervention: Eltrombopag 30 mg
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Eltrombopag 50 mg
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Eltrombopag 75 mg
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 16042648

Group type: EXPERIMENTAL
Intervention: High resistance group (standardized patient portraying high resistance)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Low resistance group (standardized patient portraying low resistance)
Number of subjects: 32
Study: 12405489

Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 10443608

Group type: EXPERIMENTAL
Intervention: 40 mg/kg rectal acetaminophen
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 60 mg/kg rectal acetaminophen
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 8543705

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral relapse prevention treatment
Number of subjects: 212

Group type: COMPARATOR
Intervention: Nonbehavioral treatment
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Coping skill training
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Efficacy for avoiding marijuana use
Number of subjects: 212
Study: 2196038

Group type: EXPERIMENTAL
Intervention: Translucent occluder
Number of subjects: 10

Group type: COMPARATOR
Intervention: Opaque occluder
Number of subjects: 10
Study: 7437240

Group type: EXPERIMENTAL
Intervention: Disopyramide (D)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Lignocaine (L)
Number of subjects: 7
Study: 31756547

Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy
Number of subjects: 115

Group type: COMPARATOR
Intervention: Postoperative chemotherapy
Number of subjects: 115
Study: 31810194

Group type: EXPERIMENTAL
Intervention: Qualitative Dietary Protocol (QDP; 'Diet4Hashi') applied in the experimental group.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional Dietetic Counseling (CDC) applied in the control group.
Number of subjects: 100
Study: 28164463

Group type: EXPERIMENTAL
Intervention: Closed-loop gastric electrical stimulation (CLGES) system
Number of subjects: 45
Study: 25556611

Group type: EXPERIMENTAL
Intervention: Fentanyl buccal tablet (FBT) 100-800 μg
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Continuation phase (FBT)
Number of subjects: 330
Study: 23499228

Group type: EXPERIMENTAL
Intervention: Prosthetic alignment changes (angular: 3° and 6° of flexion, extension, abduction, adduction; translational: 5mm and 10mm of anterior, posterior, medial, lateral)
Number of subjects: 11
Study: 21829747

Group type: EXPERIMENTAL
Intervention: Gatifloxacin (10 mg/kg/day for 3 days)
Number of subjects: 494

Group type: COMPARATOR
Intervention: Ciprofloxacin (30 mg/kg/day for 3 days in two divided doses)
Number of subjects: 494

Group type: EXPERIMENTAL
Intervention: Gatifloxacin
Number of subjects: 494
Study: 19951337

Group type: EXPERIMENTAL
Intervention: Acute inpatient orthopaedic‐geriatric care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subacute rehabilitation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Community‐based rehabilitation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Various orthopaedic‐geriatric models of care
Number of subjects: 0
Study: 17378192

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at Houxi (SI 3), treated once daily for 3 sessions (1 course)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Medication group with Mobike, 7.5 mg once daily
Number of subjects: 300
Study: 17010857

Group type: EXPERIMENTAL
Intervention: Aspiration of lens epithelial cells (LECs) from under the anterior capsule
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no aspiration of LECs)
Number of subjects: 100
Study: 14647218

Group type: EXPERIMENTAL
Intervention: Breakfast followed by lunch (same mixed macronutrient meal)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Lunch only (no breakfast)
Number of subjects: 2
Study: 10522582

Group type: EXPERIMENTAL
Intervention: Combined diltiazem (0.2 mg x kg(‐1)) and lidocaine (1.0 mg x kg(‐1))
Number of subjects: 60

Group type: COMPARATOR
Intervention: Diltiazem (0.2 mg x kg(‐1))
Number of subjects: 60

Group type: COMPARATOR
Intervention: Lidocaine (1.0 mg x kg(‐1))
Number of subjects: 60
Study: 8542008

Group type: EXPERIMENTAL
Intervention: Prednisone (2 mg/kg to a maximum of 60 mg)
Number of subjects: 86
Study: 1931867

Group type: EXPERIMENTAL
Intervention: Fasting plasma insulin tertile 1
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Fasting plasma insulin tertile 2
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Fasting plasma insulin tertile 3
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Fasting insulin concentration
Number of subjects: 83
Study: 7046104

Group type: EXPERIMENTAL
Intervention: Amoxycillin/clavulanic acid (A-CA) 250 mg/125 mg, taken 3 times daily for 7 days
Number of subjects: 164

Group type: COMPARATOR
Intervention: Amoxycillin 250 mg capsules, taken 3 times daily for 7 days
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Amoxycillin/clavulanic acid (A-CA) after treatment failure on amoxycillin
Number of subjects: 164
Study: 31218863

Group type: EXPERIMENTAL
Intervention: Heat-pressed ceramic RBFPDs, no cyclic loading (E0)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Zirconia ceramic RBFPDs, no cyclic loading (W0)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Heat-pressed ceramic RBFPDs exposed to 300,000 cycles of dynamic loading (E1)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Zirconia ceramic RBFPDs exposed to 300,000 cycles of dynamic loading (W1)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Maximum bite force in the premolar region
Number of subjects: 64

Group type: COMPARATOR
Intervention: Comparison between W0 and E0
Number of subjects: 64

Group type: COMPARATOR
Intervention: Comparison between E1 and W1
Number of subjects: 64

Group type: COMPARATOR
Intervention: Comparison between W0 and W1
Number of subjects: 64

Group type: COMPARATOR
Intervention: Comparison between E0 and E1
Number of subjects: 64
Study: 28161079

Group type: EXPERIMENTAL
Intervention: Active RFc therapy (90 J/cm2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham RFc therapy (1 J/cm2)
Number of subjects: 0
Study: 25599275

Group type: EXPERIMENTAL
Intervention: 1000 g fish and mussels/week for 26 weeks (50 μg selenium/day)
Number of subjects: 102

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 102
Study: 23873558

Group type: EXPERIMENTAL
Intervention: Bacterial 6-phytase (500, 1,000, or 2,000 phytase units/kg) with tricalcium phosphate (experiment 1)
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: Bacterial 6-phytase (500 or 1,000 phytase units/kg) with monocalcium phosphate (experiment 2)
Number of subjects: 496

Group type: COMPARATOR
Intervention: Negative control diet (NC)
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: Bacterial 6-phytase
Number of subjects: 496
Study: 21110034

Group type: EXPERIMENTAL
Intervention: Patient-selected music (classical, relaxing modern, smooth jazz)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Randomized music therapy (classical, relaxing modern, smooth jazz)
Number of subjects: 200

Group type: COMPARATOR
Intervention: No music
Number of subjects: 200
Study: 19819121

Group type: EXPERIMENTAL
Intervention: Intensive glycemic control (target HbA(1c) <7.0%)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Intensive glycemic control (target HbA(1c) 7.0‐7.9%)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Standard glycemic control
Number of subjects: 8
Study: 16798785

Group type: EXPERIMENTAL
Intervention: 0.03% tacrolimus ointment (TAC-O)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: 1% hydrocortisone acetate (HA) and 0.1% hydrocortisone butyrate ointment (HC-O)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control group (non-atopic dermatitis children)
Number of subjects: 121
Study: 15482582

Group type: EXPERIMENTAL
Intervention: si‐jue‐shi‐diao (dys‐regulation of thought and perception)
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: jing‐shen‐fen‐lie‐zheng (mind‐split-disease)
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: jing‐shen‐bin (mental illness)
Number of subjects: 313

Group type: COMPARATOR
Intervention: no label
Number of subjects: 313
Study: 11819709

Group type: EXPERIMENTAL
Intervention: Moxibustion with herbal medicine
Number of subjects: 46

Group type: COMPARATOR
Intervention: Salicylaye fapyridine (SASP)
Number of subjects: 46
Study: 9378531

Group type: EXPERIMENTAL
Intervention: Blood group B
Number of subjects: 6334

Group type: EXPERIMENTAL
Intervention: Rh D negative
Number of subjects: 6334

Group type: EXPERIMENTAL
Intervention: M gene
Number of subjects: 6334

Group type: EXPERIMENTAL
Intervention: M s haplotype
Number of subjects: 6334

Group type: EXPERIMENTAL
Intervention: S gene
Number of subjects: 6334

Group type: EXPERIMENTAL
Intervention: Duffy group alleles Fy (a‐b‐)
Number of subjects: 6334

Group type: EXPERIMENTAL
Intervention: Ss group alleles S‐ s‐
Number of subjects: 6334

Group type: EXPERIMENTAL
Intervention: Kidd blood group system alleles JK (a‐b‐)
Number of subjects: 6334
Study: 8473676

Group type: EXPERIMENTAL
Intervention: Combination TAO and methylprednisolone (MPn)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Combination TAO and prednisone
Number of subjects: 18

Group type: COMPARATOR
Intervention: MPn alone
Number of subjects: 18
Study: 3936866

Group type: EXPERIMENTAL
Intervention: Sandoglobulin (12 g as a 3% solution on day 0, day 5, and day 12, total of 36 g)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo preparation
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Sandoglobulin (IGIV)
Number of subjects: 150
Study: 28674819

Group type: EXPERIMENTAL
Intervention: Face-bow registration for remounting complete dentures
Number of subjects: 32

Group type: COMPARATOR
Intervention: Mean setting for remounting complete dentures
Number of subjects: 32
Study: 27292543

Group type: EXPERIMENTAL
Intervention: Timed bright light therapy
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Bedtime melatonin supplementation
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Both timed bright light therapy and bedtime melatonin
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebos only
Number of subjects: 144
Study: 24157445

Group type: EXPERIMENTAL
Intervention: Dietary fiber mixture
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 54
Study: 23135172

Group type: EXPERIMENTAL
Intervention: Continuous ART (cART)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Planned Treatment Interruption (PTI)
Number of subjects: 101
Study: 21039348

Group type: EXPERIMENTAL
Intervention: Epidural morphine (2 mg) twice per day
Number of subjects: 212
Study: 19122486

Group type: EXPERIMENTAL
Intervention: Breast feeding promotion program for working women
Number of subjects: 0
Study: 16372264

Group type: EXPERIMENTAL
Intervention: Sera from patients with acute K. pneumoniae infections
Number of subjects: 70

Group type: COMPARATOR
Intervention: Sera from healthy individuals (control group)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Immunogenic proteins identified
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Vaccine candidate genes OmpA and FepA
Number of subjects: 70
Study: 14585250

Group type: EXPERIMENTAL
Intervention: Extensive Lifestyle Management Intervention (ELMI)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 302
Study: 15200045

Group type: EXPERIMENTAL
Intervention: Topical tranexamic acid
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 10689628

Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 21

Group type: COMPARATOR
Intervention: Clorazepate
Number of subjects: 21
Study: 8941832

Group type: EXPERIMENTAL
Intervention: Manual ionic toothbrush
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 64
Study: 1773691

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Combination of Verapamil and Enalapril
Number of subjects: 47
Study: 6415987

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Oral metoclopramide from day 1 to 6
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Bromocriptine treatment from day 1 to 3
Number of subjects: 23
Study: 30368651

Group type: EXPERIMENTAL
Intervention: Cervical cancer education strategy led by community health volunteers (CHVs)
Number of subjects: 525
Study: 31529295

Group type: EXPERIMENTAL
Intervention: Vitamin K2 (200 μgr daily for 1 year)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 102
Study: 28800147

Group type: EXPERIMENTAL
Intervention: Triclosan/copolymer toothpaste
Number of subjects: 107

Group type: COMPARATOR
Intervention: Fluoride toothpaste (control)
Number of subjects: 107
Study: 26572093

Group type: EXPERIMENTAL
Intervention: F5K TV reduction program
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (usual Head Start curriculum)
Number of subjects: 160
Study: 24560477

Group type: EXPERIMENTAL
Intervention: Buccal misoprostol (400 mcg)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study: 22412143

Group type: EXPERIMENTAL
Intervention: Sorafenib 400 mg orally twice a day with capecitabine 1,000 mg/m(2) orally twice a day for days 1 to 14 of every 21-day cycle
Number of subjects: 229

Group type: COMPARATOR
Intervention: Placebo with capecitabine 1,000 mg/m(2) orally twice a day for days 1 to 14 of every 21-day cycle
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Sorafenib 400 mg orally twice a day
Number of subjects: 229

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 229
Study: 18973893

Group type: EXPERIMENTAL
Intervention: Daily 100 mg aspirin
Number of subjects: 169

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 169
Study: 17685695

Group type: EXPERIMENTAL
Intervention: Plyometric training
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Isometric training
Number of subjects: 13
Study: 16234523

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (vincristine, cisplatin, cyclophosphamide, and etoposide)
Number of subjects: 299

Group type: COMPARATOR
Intervention: Induction chemotherapy (vincristine, carboplatin, ifosfamide, and etoposide)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (both regimens)
Number of subjects: 299
Study: 11994333

Group type: EXPERIMENTAL
Intervention: High-salt diet plus potassium citrate (90 mmol/d)
Number of subjects: 60

Group type: COMPARATOR
Intervention: High-salt diet plus placebo
Number of subjects: 60
Study: 9850205

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 47
Study: 7523131

Group type: EXPERIMENTAL
Intervention: Prednisone (5 mg 4 times daily)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Flutamide (250 mg 3 times daily)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Estramustine phosphate (280 mg 2-3 times daily)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Epirubicin (100 mg/m2 i.v. every 3rd week)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Combined treatment (all drugs)
Number of subjects: 51
Study: 2790689

Group type: EXPERIMENTAL
Intervention: Double lumen central venous catheter
Number of subjects: 43

Group type: COMPARATOR
Intervention: Totally implantable venous access system
Number of subjects: 43
Study: 61389

Group type: EXPERIMENTAL
Intervention: Methandienone (100 mg/day for 6 weeks)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Methandienone
Number of subjects: 11
Study: 30911659

Group type: EXPERIMENTAL
Intervention: PIPAC with doxorubicin and cisplatin (1 PIPAC then 2 IV Chemo)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Systemic chemotherapy only
Number of subjects: 94
Study: 27639130

Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (2mA, anode: dorsolateral prefrontal cortex, cathode: orbitofrontal cortex)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo stimulation (sham stimulation)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Cue exposure
Number of subjects: 29
Study: 25772701

Group type: EXPERIMENTAL
Intervention: Gabapentin 600 mg preoperatively and 200 mg postoperatively on the day of surgery, continued at 200 mg three times daily for two days.
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 102
Study: 23687259

Group type: EXPERIMENTAL
Intervention: CT-P13
Number of subjects: 250

Group type: COMPARATOR
Intervention: INX
Number of subjects: 250
Study: 20673347

Group type: EXPERIMENTAL
Intervention: Pictogram format
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Metonym format
Number of subjects: 800

Group type: COMPARATOR
Intervention: Bar graph format with pre-intervention questionnaire
Number of subjects: 800

Group type: COMPARATOR
Intervention: Bar graph format without pre-intervention questionnaire
Number of subjects: 800
Study: 18194800

Group type: EXPERIMENTAL
Intervention: Postpartum dexamethasone
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study: 16372163

Group type: EXPERIMENTAL
Intervention: MSR patients
Number of subjects: 10

Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 10
Study: 14566252

Group type: EXPERIMENTAL
Intervention: Aprotinin (Trasylol)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 11168342

Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acid supplementation (2.08 g for 21 days)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (without diabetes)
Number of subjects: 29
Study: 9294377

Group type: EXPERIMENTAL
Intervention: Amphetamine treatment for 15 months
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Amphetamine treatment
Number of subjects: 62
Study: 8334085

Group type: EXPERIMENTAL
Intervention: Cervical cerclage
Number of subjects: 1292

Group type: COMPARATOR
Intervention: Control group (withholding cervical cerclage)
Number of subjects: 1292
Study: 3635546

Group type: EXPERIMENTAL
Intervention: Information group (received information as part of the research interview)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (received no information)
Number of subjects: 0